Log in to your Inderes Free account to see all free content on this page.

Bioretec

0.70 EUR

-1.41 %

1,699 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-1.41 %

-26.32 %

-49.09 %

-59.77 %

-69.55 %

-67.81 %

-53.45 %

-

-75.15 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Market cap

21.55M EUR

Turnover

63.64K EUR

P/E (adj.) (25e)

EV/EBIT (adj.) (25e)

P/B (25e)

EV/S (25e)

Dividend yield-% (25e)

Coverage

Recommendation

Accumulate

Target price

Updated

14.11.2025

Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 14.11.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk

Business risk

Valuation risk

Low

High

All

Research

Webcasts

Press releases

ShowingAll content types

Press release16 hours ago

Change negotiations completed at Bioretec

Bioretec: Building a new beginning

Research11/14/2025, 11:18 AM by

Bioretec: Building a new beginning

Bioretec’s Q3 business review highlighted the company’s situation and the commercial challenges of the RemeOs product family.

Regulatory press release11/13/2025, 6:30 AM

Bioretec Ltd's business review January-September 2025: Strengthening commercial foundations and strategy design

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/12/2025, 10:30 AM

Inside information: Bioretec initiates change negotiations to enance operational efficiency and competitiveness

Regulatory press release10/31/2025, 6:30 AM

Correction: Bioretec Ltd's Half-year report 2025

Regulatory press release10/27/2025, 7:14 PM

Inside information: Bioretec adjusts and restates previously reported net sales FOR H1/2025 and does not expect accelerated sales in 2025

Regulatory press release10/27/2025, 8:00 AM

Inside information: Bioretec is revising its financial targets, deems that the current financial targets will not be met and withdraws its financial targets

Press release10/1/2025, 12:00 PM

Bioretec's RemeOs™ Trauma Screw Approved for Transitional Pass-Through Payment in the U.S.

Press release10/1/2025, 12:00 PM

Bioretec's RemeOs™ Screw LAG Solid Receives CMS Transitional Pass-Through Payment in the US

Regulation of medical devices and diagnostics in Europe

Analyst Comment9/19/2025, 5:18 AM by

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

Bioretec Aiforia Technologies Nexstim Biohit Optomed Revenio Group Modulight Detection Technology Nightingale Health Bittium

Regulatory press release9/16/2025, 4:30 PM

Composition of Bioretec's Shareholders' Nomination Board

Regulatory press release9/15/2025, 2:30 PM

Inside information: Anne-Mari Matikainen appointed as Interim Chief Financial Officer of Bioretec; CFO Johanna Salko to depart before year-end

Regulatory press release9/15/2025, 12:15 PM

New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register

Regulatory press release9/12/2025, 8:00 AM

Inside information: Bioretec updates the commercialization status of RemeOs™ DrillPin

Press release9/4/2025, 12:00 PM

Bioretec Appoints Dr. Christopher W. DiGiovanni to Scientific Advisory Board

Classification of medical devices and regulatory processes in the United States

Analyst Comment9/8/2025, 9:56 AM by

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

Bioretec Nexstim Optomed Revenio Group Modulight Bittium Detection Technology

Press release9/2/2025, 12:15 PM

Bioretec Appoints Jordy Winters as Vice President of OUS Sales to Accelerate International Growth

Regulatory press release8/28/2025, 7:15 AM

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Press release8/27/2025, 1:00 PM

Bioretec Appoints Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer

Regulatory press release8/27/2025, 10:15 AM

Inside information: Bioretec Appoints Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer

Forum discussions

Here is a new company report on Bioretec from Antti. Bioretec’s Q3 business review shed light on the company’s situation and the commercial challenges of the RemeOs product family. Growth for the new product family is expected to be delayed until 2026. The company is seeking new ...

11/14/2025, 5:52 AM

by Sijoittaja-alokas

6

And here’s a link to the interview where Antti interviewed CEO Sarah Hubar-Fisher regarding Q3. Inderes Bioretec Q3'25: Necessary revisions ahead - Inderes Aika: 13.11.2025 klo 11.55 In connection with its Q3 business review, Bioretec shed light on its situation and the commercial...

11/13/2025, 11:00 AM

by Sijoittaja-alokas

6

Numbers were obtained, but no mentions of European departure. So we can assume that there is hardly any sales here yet. Likewise, for USA remeosis, Q3 was again utterly dismal. Cash is burning at a nice pace and we can expect zero profit. It would be interesting to see the breakdown...

11/13/2025, 7:09 AM

by Umpi

6

Q3 revenue only 30 thousand more than last year (approx. +4.4%). Antti’s expectation was +47.2%. EBITDA and operating loss almost in line with Antti’s forecasts. Tärkeimmät talousuutiset | Kauppalehti – 13 Nov 25 Bioretec Oy:n liiketoimintakatsaus tammi-syyskuu 2025: Vahvistamme....

11/13/2025, 6:47 AM

by Roni

4

Is it reasonable to speculate whether some entity more skilled in marketing would buy this? The product, to my understanding, is functional, but with current efforts, it’s not generating enough revenue. With the current results, it would now be driven perhaps even deeper into the...

11/12/2025, 4:51 PM

by Cezeta

4

Antti has already provided quick comments on the Q3 business review. On Thursday morning, Bioretec published its Q3 business review, which shed light on the company’s situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum...

11/13/2025, 8:02 AM

by Sijoittaja-alokas

3

Bioretec has a “breakthrough” product that the FDA and the corresponding EU agency have approved. I asked Bioretec how it’s possible that the product cannot be sold even though it is superior compared to “previous” practices. They have not responded.

11/12/2025, 6:17 PM

by KAMELI

2

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.